2013
Elucidating the Landscape of Aberrant DNA Methylation in Hepatocellular Carcinoma
Song M, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong L. Elucidating the Landscape of Aberrant DNA Methylation in Hepatocellular Carcinoma. PLOS ONE 2013, 8: e55761. PMID: 23437062, PMCID: PMC3577824, DOI: 10.1371/journal.pone.0055761.Peer-Reviewed Original ResearchConceptsDifferentially Methylated RegionsPromoter CpG islandsCpG islandsDNA methylationDifferential methylationMethylation changesGenome-wide methylation profilingDM locusGenome-wide levelDifferential methylation patternsAberrant DNA methylationPotential biological functionsSignificant differential methylationGene bodiesIllumina HumanMethylation450 BeadChipGenomic regionsIntergenic regionMethylated regionsMethylation patternsCellular developmentEpigenetic changesGene promoterGene listsMethylation profilingBiological functions
2006
Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3)
Harris T, Strickler H, Yu H, Pollak M, Monrad E, Travin M, Xue X, Rohan T, Kaplan R. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). Growth Hormone & IGF Research 2006, 16: 86-92. PMID: 16530441, DOI: 10.1016/j.ghir.2006.01.002.Peer-Reviewed Original ResearchConceptsFree IGF-I levelsIGF-I levelsInsulin-like growth factorTotal IGFIGFBP-3 levelsFree IGFIGFBP-3Blood specimensBlood collectionEpidemiologic studiesTotal insulin-like growth factorSerum separation tubesGrowth factorRisk of cancerEquation linear regression modelsSerum levelsCardiovascular diseaseMajor binding proteinSerum valuesIGFCommercial assaysIGFBPSpecimen processing timeProtein 3Immunosorbent assay
2000
Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up
Vassilikos E, Yu H, Trachtenberg J, Nam R, Narod S, Bromberg I, Diamandis E. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clinical Biochemistry 2000, 33: 115-123. PMID: 10751589, DOI: 10.1016/s0009-9120(99)00099-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease-Free SurvivalFluorescent Antibody TechniqueFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsProstatectomyProstate-Specific AntigenProstatic NeoplasmsRecurrenceRegression AnalysisReproducibility of ResultsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsProstate cancer patientsRadical prostatectomySerum PSACancer patientsPSA assaysUltrasensitive prostate specific antigenPre-operative PSAGroup of patientsSerial serum samplesEarly therapeutic interventionSeminal vesicle invasionSurgical margin positivityProstate-specific antigenRegular PSAUltrasensitive PSAPSA increaseMargin positivityClinical stageGleason scorePrognostic indicatorCapsular invasionTissue involvementTumor volumePatientsFast relapse